Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-17.27%||ROE||-20.31%||ROI|
|Current Ratio||10.38||Quick Ratio||Long Term Debt/Equity||0.02||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||40 K||Cash From Investing Activities||1.86 M||Cash From Operating Activities||-5.12 M||Gross Profit|
|Net Profit||-14.04 M||Operating Profit||-14.23 M||Total Assets||165.61 M||Total Current Assets||124.49 M|
|Total Current Liabilities||12 M||Total Debt||1.94 M||Total Liabilities||24.75 M||Total Revenue|
|High 52 week||14.82||Low 52 week||5.31||Last close||5.31||Last change||0%|
|RSI||18.73||Average true range||0.46||Beta||1.1||Volume||98.87 K|
|Simple moving average 20 days||-18.35%||Simple moving average 50 days||-30.51%||Simple moving average 200 days||-40.72%|
|Performance Week||-7.17%||Performance Month||-40.67%||Performance Quart||-38.04%||Performance Half||-55.27%|
|Performance Year||-54.54%||Performance Year-to-date||-26.15%||Volatility daily||3.7%||Volatility weekly||8.28%|
|Volatility monthly||16.97%||Volatility yearly||58.78%||Relative Volume||231.19%||Average Volume||645.15 K|
|New High||New Low|
2019-11-13 16:05:00 | Dermira Elects Halley E. Gilbert to its Board of Directors
2019-11-08 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2019-11-08 10:18:03 | Short Seller Scores Big Win as Tiny Biotech Stock Sinks 72%
2019-11-08 10:04:03 | The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks
2019-11-07 09:17:02 | Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks
2019-11-07 06:07:36 | 3 Biotech Stocks Needham Expects to Double in the Next 12 Months
2019-11-06 10:36:03 | Jazz Pharma JAZZ Q3 Earnings Beat, Xyrem Drives Sales
2019-11-06 02:08:21 | Edited Transcript of DERM earnings conference call or presentation 5-Nov-19 9:30pm GMT
2019-11-05 19:15:12 | Dermira DERM Reports Q3 Loss, Tops Revenue Estimates
2019-11-05 16:05:00 | Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-10-25 09:03:58 | Did You Manage To Avoid Dermira's NASDAQ:DERM Devastating 79% Share Price Drop?
2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-10-14 10:28:02 | Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
2019-10-10 09:57:01 | Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
2019-10-08 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
2019-09-26 16:05:00 | Dermira to Participate in the 2019 Cantor Global Healthcare Conference
2019-09-10 12:24:45 | How Much Are Dermira, Inc. NASDAQ:DERM Insiders Spending On Buying Shares?
2019-08-29 16:05:00 | Dermira to Participate in Upcoming Investor Conferences
2019-08-20 00:15:17 | Dermira Inc DERM CEO & Chairman of the Board Thomas G Wiggans Bought $199,998 of Shares
2019-08-08 12:00:08 | Edited Transcript of DERM earnings conference call or presentation 7-Aug-19 8:30pm GMT
2019-08-07 19:45:11 | Dermira DERM Reports Q2 Loss, Tops Revenue Estimates
2019-08-07 16:05:00 | Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update
2019-07-29 10:34:02 | Earnings Preview: Dermira DERM Q2 Earnings Expected to Decline
2019-07-25 13:03:48 | 5 Biotech Stocks to Buy for Blockbuster Potential
2019-07-24 15:15:48 | Should You Be Pleased About The CEO Pay At Dermira, Inc.'s NASDAQ:DERM
2019-07-01 09:15:01 | Stocks Soar 7% in June
2019-06-11 16:00:00 | Dermira to Present at the Raymond James Life Sciences and MedTech Conference
2019-06-11 08:05:48 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-06-10 08:05:02 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-06-06 13:34:00 | Dermira Advances on Analyst Upgrade to Buy
2019-06-06 08:05:15 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-06-04 08:03:27 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-05-08 15:24:17 | Dermira DERM Q1 2019 Earnings Call Transcript
2019-05-08 11:13:10 | Did You Manage To Avoid Dermira's NASDAQ:DERM Painful 63% Share Price Drop?
2019-05-08 01:11:11 | Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT
2019-05-07 19:25:11 | Dermira DERM Reports Q1 Loss, Lags Revenue Estimates
2019-05-07 18:19:15 | Dermira: 1Q Earnings Snapshot
2019-05-07 16:05:00 | Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
2019-05-07 08:03:19 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-04-25 10:34:02 | Dermira DERM May Report Negative Earnings: Know the Trend Ahead of Q1 Release